Printer Friendly

Idun Pharmaceuticals Highlights the Importance of Targeting Apoptosis for the Treatment of Congestive Heart Failure.

- Implications for Drug Development Being Presented

at Cardiovascular Summit 2000 -

LONDON, Oct. 2 /PRNewswire/ --

Idun Pharmaceuticals, Inc. today presented research on myocyte (heart muscle cell) apoptosis and its potential application for the development of new therapeutics for congestive heart failure (CHF) at the Cardiovascular Summit 2000 in London. Dr. Steven Mento, President and Chief Executive Officer of Idun Pharmaceuticals discussed the significance of apoptosis in heart failure, its possible role as a prognostic indicator and research aimed at uncovering the molecular pathways implicated in myocyte apoptosis.

In successful collaborations with academic institutions, Idun Pharmaceuticals has employed cellular models to decipher the role of myocyte apoptosis in congestive heart failure and identify potential drug targets arising from the elucidation of critical molecular pathways. Using elements of its technology to understand the role of apoptosis, the company is determining the value of caspase inhibitors in delaying the progression of this disease.

"This was an opportunity for Idun to discuss the latest developments in congestive heart failure in an open forum with other leading experts," said Dr. Mento. "CHF is one of a wide range of indications currently being investigated by Idun as potential applications for drugs which target the critical cellular process of apoptosis."

Congestive heart failure is a condition that occurs when the heart cannot pump enough blood to meet the needs of the body's other organs. As a result, the heart is not as efficient as it should be and it becomes significantly weaker over time. More than 5 million Americans suffer from congestive heart failure and it is the leading cause of hospitalization among people aged 65 and older.

Idun Pharmaceuticals, Inc. is a biopharmaceutical company based in La Jolla, CA. It creates innovative human therapeutics with a primary focus on controlling apoptosis, or programmed cell death. Idun believes that controlling the cell death process will have utility in treating cancer, neurodegenerative diseases, ischemic disorders and cardiovascular disease. The company has adopted a commercialization strategy encompassing strategic collaborations with major pharmaceutical companies; internal, independent development of selected small molecule therapeutics, and out-licensing of diagnostics, gene therapies, and bioproduction technologies. Idun has a broad patent portfolio covering the fundamental and core technologies involved in the regulation of cell death and has established partnerships with Novartis in central nervous system diseases, with Abbott in cancer, with Elan in stroke, and Becton Dickinson in research reagents. For more information, please visit the company's Web site at .


Steven J. Mento, Ph.D.

President and CEO

Idun Pharmaceuticals, Inc.

(858) 623-1330

Noonan/Russo Communications, Inc.

Lora Pike (media)

(415) 677-4455, ext. 211
COPYRIGHT 2000 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2000 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Geographic Code:1USA
Date:Oct 2, 2000
Previous Article:How Many Kids Have to Die From Gun Violence Before it's Too Many?
Next Article:Fire Prevention Week Is Ideal Time to Plan Home Fire Protection.

Terms of use | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters